过去几年中，碳酸酐酶抑制剂局部应用对青光眼的治疗进行了广泛的研究，其中最有希望的药物是ｔｈｉｅｎｏｔｈｉｏｐｙｒａｎ－２－ｓｕｌｆｏｎａｍｉｄｅｓ类化合物的衍生物。研究表明，它们可与β受体阻滞剂联合应用，也可与大多数其它局部应用的治疗青光眼的药物联合应用，有协同作用。它们是通过减少房水生成来降低眼内压的。其副作用包括局部刺激和变态反应。全身性副作用如电解质紊乱，造血障碍等尚未发现，剂量依赖性造血障碍的发生，在减少用量的情况下可能会减少，非剂量依赖性造血障碍在少数特异体质患者身上可能会发生。 Over the past few years, the topical use of carbonic anhydrase inhibitors has been extensively studied in the treatment of glaucoma, the most promising of which is a derivative of thienothiopyran-2-sulfonamides. Studies have shown that they can be combined with β-blockers, but also synergistically with most other topical glaucoma drugs. They reduce intraocular pressure by reducing aqueous humor production. Side effects include local irritation and allergies. Systemic side effects such as electrolyte disturbances, hematopoietic disorders and the like have not been found. Dose-dependent hematopoietic disorders may be reduced at reduced doses and non-dose-dependent hematopoietic disorders may occur in a minority of patients with idiosyncratic disease.